Used in targeted cancer therapy, particularly for advanced gastric, colorectal, and non-small cell lung cancers. Binds to the VEGFR2 receptor on endothelial cells, blocking vascular endothelial growth factor (VEGF) signaling. This inhibition suppresses tumor angiogenesis—formation of new blood vessels that supply tumors—thereby limiting tumor growth and metastasis. Administered intravenously, often in combination with chemotherapy, especially in patients who have progressed on prior treatments. Its specificity for VEGFR2 minimizes damage to healthy tissues compared to conventional chemotherapy, offering a more targeted approach with a manageable side effect profile.